Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia 2Depression 2Tuberous Sclerosis 1Tourette Syndrome 1Tic Disorders 1Preleukemia 1Neurodevelopmental Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hot Flashes 1Hematologic Diseases 1Glioblastoma 1Fragile X Syndrome 1DiGeorge Syndrome 1Cytopenia 1Breast Neoplasms 1Bone Marrow Diseases 1Autistic Disorder 1Autism Spectrum Disorder 1Attention Deficit Disorder with Hyperactivity 1Anxiety Disorders 1Anemia 122q11 Deletion Syndrome 1

Interventions

Acupuncture Therapy 10Gabapentin 7Venlafaxine Hydrochloride 5Tamoxifen 3Isoflavones 3Estrogens, Conjugated (USP) 3Bupivacaine 3liposomal amphotericin B 2fezolinetant 2black cohosh root extract 2Soybean Proteins 2Sodium Chloride 2Moxifloxacin 2Magnesium Oxide 2Hypnosis 2Control Groups 2Citalopram 2Caspofungin 2zopiclone 1oxybutynin 1bazedoxifene 1Zolpidem 1Vitamin B 6 1Vancomycin 1Therapeutics 1Testosterone 1Tazobactam 1Tablets 1Sugars 1Solifenacin Succinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hot Flashes × Sertraline × Clear all
NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Mayo Clinic

Completed
88 enrolled
Breast

Breast Neoplasms, Depression, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡